Last checked at 25 Jan 2016 07:00
25 January 2016
Port Erin Biopharma Investments Limited
(the "Company")
Net Asset Value calculation to 31 December 2015
Jim Mellon, Chairman, commented: -
"The Net Asset Value ("NAV") calculation for the Company as at closing on 31 December 2015 was 10.79 pence per share, including un-invested cash of £24,011. The portfolio is valued under IFRS at bid price.
Net Assets stand at £2.5 million including Investments of £2.49 million. This quarter's NAV represents an increase of 7.47% from the previous valuation of 10.04 pence per share, which included un-invested cash of £67,542. No additional management fee is due to Shellbay Investments Limited.
The reported NAV to 31 December 2015 gained due to strong performance across the portfolio during the quarter. The company's three principal investments continue to show significant growth prospects for 2016 and beyond".
Unaudited to 31 December 2015 £ | ||
Fixed Assets | ||
Investments | 2,494,733 | |
Current Assets | ||
Sundry Debtors | 6,342 | |
Uninvested cash | 24,011 | |
Current Liabilities | ||
Creditors: amounts due | (23,192) | |
2,501,894 | ||
Capital and Reserves | ||
Share Capital | 23 | |
Share Premium | 1,890,142 | |
Reserves | 611,729 | |
2,501,894 | ||
Shares in Issue | 23,195,558 | |
Net Asset Value per share | 10.79 pence |
Portfolio Details
Investments as at 31 December 2015 | Value | % of Total Portfolio | |
Magna Biopharma Income Fund | £1,241,145 | 49.8% | |
Plethora Solutions Holdings | £348,746 | 14.0% | |
Summit Corporation | £438,378 | 17.6% | |
Other quoted holdings | £229,826 | 9.2% | |
Other unquoted holdings | £236,638 | 9.4% | |
Total | £2,494,733 | 100.0% | |
For further information, please contact:
Port Erin Biopharma Investments Limited | Beaumont Cornish Limited | Peterhouse Capital Limited |
The Company | Nomad | Broker |
Denham Eke (+44) (0) 1624 639396 | Roland Cornish/ James Biddle (+44) (0) 207 628 3396 | Lucy Williams (+44) (0) 207 469 0936 |